Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer.

In contrast, while DOAC use was associated with a reduced risk of other critical‐site bleeding (sHR, 0.17; 95% CI, 0.05–0.58; p < 0.01), it was linked to an increased risk of gastrointestinal bleeding (sHR, 3.00; 95% CI, 1.94–4.64; p < 0.01), alongside a nonsignificant trend toward lower intracranial hemorrhage risk (sHR, 0.79; 95% CI, 0.47–1.33; p = 0.37) compared with LMWH use. 3.4 Subgroup Analyses Focusing on Recurrent VTE and Bleeding As illustrated in Figure 3A , our subgroup analysis of recurrent VTE associated with GI cancer highlights that patients under 65 years of age demonstrated a reduced risk of VTE when treated with DOACs.

also in 5,406 other papers